Edwards Lifesciences R&D decreased by 1.6% to $263.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.4%, from $254.60M to $263.30M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 4.6% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
High spending signals a commitment to future growth and innovation, though it reduces current period earnings.
Detailed definition
Expenses related to the development of new products, services, and technologies, as well as the improvement of existing...
Peer comparison
Tech leaders often spend a significant percentage of revenue on R&D to prevent disruption by competitors.
Metric ID:
research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $225.30M | $238.00M | $232.80M | $228.60M | $250.80M | $233.60M | $232.20M | $261.20M | $270.30M | $270.30M | $270.00M | $285.20M | $272.60M | $253.40M | $241.80M | $254.60M | $276.20M | $280.70M | $267.70M | $263.30M |
| QoQ Change | — | +5.6% | -2.2% | -1.8% | +9.7% | -6.9% | -0.6% | +12.5% | +3.5% | +0.0% | -0.1% | +5.6% | -4.4% | -7.0% | -4.6% | +5.3% | +8.5% | +1.6% | -4.6% | -1.6% |
| YoY Change | — | — | — | — | +11.3% | -1.8% | -0.3% | +14.3% | +7.8% | +15.7% | +16.3% | +9.2% | +0.9% | -6.3% | -10.4% | -10.7% | +1.3% | +10.8% | +10.7% | +3.4% |
Range$225.30M – $285.20M
CAGR+3.3%
Avg YoY Growth+4.5%
Median YoY Growth+5.6%
Current Streak2 quarters decline
R&D at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's r&d?
- Edwards Lifesciences (EW) reported r&d of $263.30M in Q1 2026.
- How has Edwards Lifesciences's r&d changed year-over-year?
- Edwards Lifesciences's r&d increased by 3.4% year-over-year, from $254.60M to $263.30M.
- What is the long-term trend for Edwards Lifesciences's r&d?
- Over 4 years (2021 to 2025), Edwards Lifesciences's r&d has grown at a 4.6% compound annual growth rate (CAGR), from $903.10M to $1.08B.
- What does r&d mean?
- The money spent on creating new technology and improving existing products.